ReviewCurrent genetics2013
Recent insights into Candida albicans biofilm resistance mechanisms.
Review in Current genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03115073 (A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001), which is not on this map. Cited by 129 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcriptomic meta-analysis to identify potential antifungal targets in Candida albicans.BMC microbiology · 2024Pooled it
- Article
- Thermoresponsive carbohydrate polymer mucoadhesive gel for synergistic delivery of acarbose and fluconazole against Candida biofilms.Scientific reports · 2026Article
- OvercomingFrontiers in antibiotics · 2026Review
- Coriander leaf essential oil as an immunomodulator: Enhancing NF-κB-driven RAW246.7 murine macrophages response to Candida albicans.PloS one · 2026Article
- Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026Review
- Bioactive Constituents ofDrug design, development and therapy · 2026Review
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Impact of Biofilm Formation by VaginalJournal of fungi (Basel, Switzerland) · 2025Article
- Antifungal Nanocomposites from Honeybee Chitosan and Royal Jelly-Mediated Nanosilver for Suppressing Biofilm and Hyphal Formation ofPolymers · 2025Article
- Article
- Biochemical and Physiological Profiles ofLife (Basel, Switzerland) · 2025Article
- Antifungal effects of Metformin against Candida albicans by autophagy regulation.Journal of microbiology (Seoul, Korea) · 2025Article
- Synthesis and evaluation of the antifungal and antibiofilm potential of aminochalcones.Archives of microbiology · 2025Article
- Phenotypic and genotypic characterization ofJournal of oral microbiology · 2025Article
- Nano Selenium: A Promising Solution for Infectious Diseases - Current Status and Future Prospects.Current pharmaceutical design · 2025Review
- Anti-Candida activity and biocompatibility of silver nanoparticles associated with denture glaze: a new approach to the management of denture stomatitis.Folia microbiologica · 2024Article
- Exploring the Antibiofilm Effect of Sertraline in Synergy withPharmaceuticals (Basel, Switzerland) · 2024Article
- Antifungal susceptibility and virulence determinants profile of candida species isolated from patients with candidemia.Scientific reports · 2024Article
- An improved expression and purification protocol enables the structural characterization of Mnt1, an antifungal target from Candida albicans.Fungal biology and biotechnology · 2024Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Like other microorganisms, free-living Candida albicans is mainly present in a three-dimensional multicellular structure, which is called a biofilm, rather than in a planktonic form. Candida albicans biofilms can be isolated from both abiotic and biotic surfaces at various locations within the host. As the number of abiotic implants, mainly bloodstream and urinary catheters, has been increasing, the number of biofilm-associated bloodstream or urogenital tract infections is also strongly increasing resulting in a raise in mortality. Cells within a biofilm structure show a reduced susceptibility to specific commonly used antifungals and, in addition, it has recently been shown that such cells are less sensitive to killing by components of our immune system. In this review, we summarize the most important insights in the mechanisms underlying biofilm-associated antifungal drug resistance and immune evasion strategies, focusing on the most recent advances in this area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.